ABSTRACT
Prostate cancer (PCa) is the most common cancer among men in the United States. The paradigm of cancer care in the future will be a risk-adjusted patient-specific therapy designed to maximize cancer control while minimizing the risk of complications. PCa screening is typically performed with a digital rectal examination and measurement of serum PSA level. Antibodies directed at the extracellular domain may increase the sensitivity of PSMA antibody imaging of PCa by recognizing surface epitopes on living cancer cells. The American Cancer Society estimates 218,890 new cases of PCa in 2007, 29% of all sites in men, causing mortality in 27,050 or 9% of all male cancer deaths. Imaging has become increasingly important in the assessment of PCa management because of the need for help with treatment selection and planning. Conventional anatomic imaging methods like computed tomography, ultrasound, or magnetic resonance imaging are insufficiently accurate for determination of the initial tumor stage because of their low sensitivities and specificities.
